Literature DB >> 12647309

Nuclear trafficking of FGFR1: a role for the transmembrane domain.

Jason M Myers1, Gabriel G Martins, Jacek Ostrowski, Michal K Stachowiak.   

Abstract

Several members of the fibroblast growth factor (FGF) family lack signal peptide (SP) sequences and are present only in trace amounts outside the cell. However, these proteins contain nuclear localization signals (NLS) and accumulate in the cell nucleus. Our studies have shown that full length FGF receptor 1 (FGFR1) accumulates within the nuclear interior in parallel with FGF-2. We tested the hypothesis that an atypical transmembrane domain (TM) plays a role in FGFR1 trafficking into the nuclear interior. With FGFR1 destined for constitutive fusion with the plasma membrane due to its SP, how the receptor may enter the nucleus is unclear. Sequence analysis identified that FGFR1 has an atypical TM containing short stretches of hydrophobic amino acids (a.a.) interrupted by polar a.a. The beta-sheet is the predicted conformation of the FGFR1 TM, in contrast to the alpha-helical conformation of other single TM tyrosine kinase receptors, including FGFR4. Receptor trafficking in live cells was studied by confocal microscopy via C-terminal FGFR1 fusions to enhanced green fluorescent protein (EGFP) and confirmed by subcellular fractionation and Western immunoblotting. Nuclear entry of FGFR1-EGFP was independent of karyokinessis, and was observed in rapidly proliferating human TE671 cells, in slower proliferating glioma SF763 and post-mitotic bovine adrenal medullary cells (BAMC). In contrast, a chimeric FGFR1/R4-EGFP, where the TM of FGFR1 was replaced with that of FGFR4, was associated with membranes (golgi-ER, plasma, and nuclear), but was absent from the nucleus and cytosol. FGFR1delta-EGFP mutants, with hydrophobic TM a.a. replaced with polar a.a., showed reduced association with membranes and increased cytosolic/nuclear accumulation with an increase in TM hydrophilicity. FGFR1(TM-)-EGFP (TM deleted), was detected in the golgi-ER vesicles, cytosol, and nuclear interior; thus demonstrating that the FGFR1 TM does not function as a NLS. To test whether cytosolic FGFR1 provides a source of nuclear FGFR1, cells were transfected with FGFR1(SP-) (SP was deleted), resulting in cytosolic, non-membrane, protein accumulation in the cytosol and the cell nucleus. Our results indicate that an unstable association with cellular membranes is responsible for the release of FGFR1 into the cytosol and cytosolic FGFR1 constitutes the source of the nuclear receptor. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12647309     DOI: 10.1002/jcb.10476

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  31 in total

1.  H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism.

Authors:  Mei-Kuang Chen; Yi Du; Linlin Sun; Jennifer L Hsu; Yu-Han Wang; Yuan Gao; Jiaxing Huang; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

Review 2.  Biological function of nuclear receptor tyrosine kinase action.

Authors:  Sungmin Song; Kenneth M Rosen; Gabriel Corfas
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

Review 3.  Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.

Authors:  Y-N Wang; H Yamaguchi; J-M Hsu; M-C Hung
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

Review 4.  Nuclear Fibroblast Growth Factor Receptor Signaling in Skeletal Development and Disease.

Authors:  Creighton T Tuzon; Diana Rigueur; Amy E Merrill
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

5.  Blocking Infralimbic Basic Fibroblast Growth Factor (bFGF or FGF2) Facilitates Extinction of Drug Seeking After Cocaine Self-Administration.

Authors:  Madalyn Hafenbreidel; Robert C Twining; Carolynn Rafa Todd; Devin Mueller
Journal:  Neuropsychopharmacology       Date:  2015-05-21       Impact factor: 7.853

6.  Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling.

Authors:  Amy E Merrill; Anna Sarukhanov; Pavel Krejci; Brian Idoni; Natalia Camacho; Kristine D Estrada; Karen M Lyons; Hannah Deixler; Haynes Robinson; David Chitayat; Cynthia J Curry; Ralph S Lachman; William R Wilcox; Deborah Krakow
Journal:  Am J Hum Genet       Date:  2012-03-01       Impact factor: 11.025

7.  Activation of developmental nuclear fibroblast growth factor receptor 1 signaling and neurogenesis in adult brain by α7 nicotinic receptor agonist.

Authors:  Sridhar T Narla; Ilona Klejbor; Barbara Birkaya; Yu-Wei Lee; Janusz Morys; Ewa K Stachowiak; Dorota Prokop; Merouane Bencherif; Michal K Stachowiak
Journal:  Stem Cells Transl Med       Date:  2013-09-06       Impact factor: 6.940

8.  Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Authors:  Luigi Formisano; Kimberly M Stauffer; Christian D Young; Neil E Bhola; Angel L Guerrero-Zotano; Valerie M Jansen; Mónica M Estrada; Katherine E Hutchinson; Jennifer M Giltnane; Luis J Schwarz; Yao Lu; Justin M Balko; Olivier Deas; Stefano Cairo; Jean-Gabriel Judde; Ingrid A Mayer; Melinda Sanders; Teresa C Dugger; Roberto Bianco; Thomas Stricker; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

9.  ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response.

Authors:  Basak Icli; Ajit Bharti; Laura Pentassuglia; Xuyang Peng; Douglas B Sawyer
Journal:  Biochem Biophys Res Commun       Date:  2012-01-05       Impact factor: 3.575

10.  Nuclear translocation of beta-dystroglycan reveals a distinctive trafficking pattern of autoproteolyzed mucins.

Authors:  Maria Luisa Oppizzi; Armin Akhavan; Manisha Singh; Jimmie E Fata; John L Muschler
Journal:  Traffic       Date:  2008-09-18       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.